Plus Therapeutics Sets 2026 Milestones For REYOBIQ Clinical Program And CNSide Commercial Rollout

Plus Therapeutics completed a $15 million upsized offering to accelerate its REYOBIQ targeted radiotherapeutic program and scale commercialization of the CNSide diagnostic platform, extending cash runway through 2027 with $16.6 million in cash at end-Q3 2025. Material 2026 milestones include ReSPECT-LM dose/interval data expected in Q3 2026, ReSPECT-GBM enrollment completion and an FDA end-of-phase meeting with data expected in Q4 2026, initiation of a pediatric ReSPECT-PBC Phase 1 trial, and CNSide commercialization targets (coverage to 150 million U.S. lives, Medicare/Medicaid coverage, and >1,250 annual commercial tests); the stock was trading pre-market at $0.31, up ~7.6%.

Analysis

Contrarian view: Consensus likely overweights the commercial potential of CNSide given the modest operational target of >1,250 tests/year and the long timeline for Medicare inclusion; the market may be underestimating dilution risk despite the $15M raise and stated runway to 2027. Conversely, the market may underprice the upside if PSTV secures a favorable Medicare decision or an expedited FDA pathway—these binary events could drive >2x moves from current sub‑$1 levels. Historical parallels: small radiopharma names repeatedly show low‑probability/high‑payoff binary behavior — successful regulatory/reimbursement outcomes rerate valuation sharply but failures destroy equity. Unintended consequence: aggressive commercialization spending to hit coverage targets could accelerate cash burn and force near‑term equity raises that compress upside for existing shareholders.

Key Decisions for Investors

• Establish a tactical 2–3% long position in PSTV (plus Therapeutics) across 3 tranches: 40% now, 30% on confirmation of manufacturing scale‑up, 30% on enrollment milestones through H1 2026; have a hard stop loss at a 40% drawdown from entry.
• Implement a relative‑value pair: long PSTV (size above) and short XBI (equal dollar notional) to neutralize biotech beta, review quarterly and unwind if PSTV shows sustained outperformance >30% or XBI underperforms by >15%.
• Buy a Jan 2027 PSTV call spread (buy deep ITM/ATM if available or 0.50 delta, sell 0.20 delta) sized to 0.5–1% portfolio risk to capture late‑2026 readouts; simultaneously buy 30–60 day puts (small size) to protect against near‑term dilution announcements.
• Do not overweight sector; limit total biotech micro‑cap exposure to <5% of portfolio until Medicare coverage clarity or positive ReSPECT data (Q3–Q4 2026) materializes.